Anti‐interleukin‐6 signalling therapy rebalances the disrupted cytokine production of B cells from patients with active rheumatoid arthritis

Publisher： John Wiley & Sons Inc

E-ISSN： 1521-4141|48|1|194-203

ISSN： 0014-2980

Source： EUROPEAN JOURNAL OF IMMUNOLOGY, Vol.48, Iss.1, 2018-01, pp. : 194-203

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Brief Report: Leucine‐Rich α2‐Glycoprotein as a Potential Biomarker for Joint Inflammation During Anti–Interleukin‐6 Biologic Therapy in Rheumatoid Arthritis

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 8, 2015-05 ,pp. : 2056-2060

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and Safety of Anti–Interleukin‐20 Monoclonal Antibody in Patients With Rheumatoid Arthritis: A Randomized Phase IIa Trial

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 6, 2015-06 ,pp. : 1438-1448

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of disease‐mediated therapeutic protein–drug interactions between an anti–interleukin‐6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 12, 2015-12 ,pp. : 1386-1394

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anti‐Interleukin Therapy in Asthma

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 97, Iss. 1, 2015-01 ,pp. : 55-65

John Wiley & Sons Inc

Access to resources Recommend Favorite

Activation of Syk in Peripheral Blood B Cells in Patients With Rheumatoid Arthritis: A Potential Target for Abatacept Therapy

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 1, 2015-01 ,pp. : 63-73

John Wiley & Sons Inc

Access to resources Recommend Favorite